Austin A Robinson1, Cory R Trankle2, Grayson Eubanks3, Christopher Schumann1, Paul Thompson4, Ryan L Wallace2, Shouri Gottiparthi3, Benjamin Ruth1, Christopher M Kramer1,5, Michael Salerno1,5,6, Kenneth C Bilchick1, Cody Deen3, Michael C Kontos2, John Dent1. 1. Division of Cardiovascular Medicine, Department of Medicine, University of Virginia Health System, Charlottesville. 2. Virginia Commonwealth University Pauley Heart Center, Virginia Commonwealth University, Richmond. 3. Department of Medicine, University of North Carolina, Chapel Hill. 4. Department of Internal Medicine, Scripps Health, La Jolla, California. 5. Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville. 6. Cardiovascular Imaging Center, Department of Biomedical Engineering, University of Virginia Health System, Charlottesville.
Abstract
Importance: Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of direct oral anticoagulants (DOACs) for this indication. Objective: To compare the outcomes associated with DOAC use and warfarin use for the treatment of LV thrombi. Design, Setting, and Participants: A cohort study was performed at 3 tertiary care academic medical centers among 514 eligible patients with echocardiographically diagnosed LV thrombi between October 1, 2013, and March 31, 2019. Follow-up was performed through the end of the study period. Exposures: Type and duration of anticoagulant use. Main Outcomes and Measures: Clinically apparent SSE. Results: A total of 514 patients (379 men; mean [SD] age, 58.4 [14.8] years) with LV thrombi were identified, including 300 who received warfarin and 185 who received a DOAC (64 patients switched treatment between these groups). The median follow-up across the patient cohort was 351 days (interquartile range, 51-866 days). On unadjusted analysis, DOAC treatment vs warfarin use (hazard ratio [HR], 2.71; 95% CI, 1.31-5.57; P = .01) and prior SSE (HR, 2.13; 95% CI, 1.22-3.72; P = .01) were associated with SSE. On multivariable analysis, anticoagulation with DOAC vs warfarin (HR, 2.64; 95% CI, 1.28-5.43; P = .01) and prior SSE (HR, 2.07; 95% CI, 1.17-3.66; P = .01) remained significantly associated with SSE. Conclusions and Relevance: In this multicenter cohort study of anticoagulation strategies for LV thrombi, DOAC treatment was associated with a higher risk of SSE compared with warfarin use, even after adjustment for other factors. These results challenge the assumption of DOAC equivalence with warfarin for LV thrombi and highlight the need for prospective randomized clinical trials to determine the most effective treatment strategies for LV thrombi.
Importance: Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of direct oral anticoagulants (DOACs) for this indication. Objective: To compare the outcomes associated with DOAC use and warfarin use for the treatment of LV thrombi. Design, Setting, and Participants: A cohort study was performed at 3 tertiary care academic medical centers among 514 eligible patients with echocardiographically diagnosed LV thrombi between October 1, 2013, and March 31, 2019. Follow-up was performed through the end of the study period. Exposures: Type and duration of anticoagulant use. Main Outcomes and Measures: Clinically apparent SSE. Results: A total of 514 patients (379 men; mean [SD] age, 58.4 [14.8] years) with LV thrombi were identified, including 300 who received warfarin and 185 who received a DOAC (64 patients switched treatment between these groups). The median follow-up across the patient cohort was 351 days (interquartile range, 51-866 days). On unadjusted analysis, DOAC treatment vs warfarin use (hazard ratio [HR], 2.71; 95% CI, 1.31-5.57; P = .01) and prior SSE (HR, 2.13; 95% CI, 1.22-3.72; P = .01) were associated with SSE. On multivariable analysis, anticoagulation with DOAC vs warfarin (HR, 2.64; 95% CI, 1.28-5.43; P = .01) and prior SSE (HR, 2.07; 95% CI, 1.17-3.66; P = .01) remained significantly associated with SSE. Conclusions and Relevance: In this multicenter cohort study of anticoagulation strategies for LV thrombi, DOAC treatment was associated with a higher risk of SSE compared with warfarin use, even after adjustment for other factors. These results challenge the assumption of DOAC equivalence with warfarin for LV thrombi and highlight the need for prospective randomized clinical trials to determine the most effective treatment strategies for LV thrombi.
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: John W Eikelboom; Stuart J Connolly; Martina Brueckmann; Christopher B Granger; Arie P Kappetein; Michael J Mack; Jon Blatchford; Kevin Devenny; Jeffrey Friedman; Kelly Guiver; Ruth Harper; Yasser Khder; Maximilian T Lobmeyer; Hugo Maas; Jens-Uwe Voigt; Maarten L Simoons; Frans Van de Werf Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: Keaton S Smetana; Jessie Dunne; Kevin Parrott; George A Davis; Amy C Schmelzer Collier; Mary Covell; Susan Smyth Journal: J Thromb Thrombolysis Date: 2017-11 Impact factor: 2.300
Authors: Nicklas Vinter; Marie Linder; Morten Andersen; Alma B Pedersen; Morten Madsen; Stephen E Schachterle; Quazi Ataher; Jingping Mo; Søren Paaske Johnsen; Vera Ehrenstein Journal: Pharmacoepidemiol Drug Saf Date: 2019-04-16 Impact factor: 2.890
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Megan E Bass; Tyree H Kiser; Robert L Page; Colleen K McIlvennan; Larry A Allen; Garth Wright; Courtney Shakowski Journal: J Thromb Thrombolysis Date: 2021-01-09 Impact factor: 2.300
Authors: Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson Journal: Blood Date: 2021-05-20 Impact factor: 22.113
Authors: Abdullah Al-Abcha; Khader Herzallah; Yehia Saleh; Mark Mujer; Ola Abdelkarim; Mahmoud Abdelnabi; Abdallah Almaghraby; George S Abela Journal: Am J Cardiovasc Drugs Date: 2020-12-23 Impact factor: 3.571